Status:
UNKNOWN
Ozurdex in Reducing PVR After Vitreotomy in PDR
Lead Sponsor:
Peking University People's Hospital
Conditions:
Diabetic Retinopathy
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Diabetic retinopathy is a significant source of visual morbidity in the adult population. Complications of diabetic retinopathy include ischemic maculopathy, macular edema, and sequelae of fibrovascul...
Detailed Description
Diabetic retinopathy is a significant source of visual morbidity in the adult population. Complications of diabetic retinopathy include ischemic maculopathy, macular edema, and sequelae of fibrovascul...
Eligibility Criteria
Inclusion
- macula off treatment naive TRD second to PDR causing visual loss;
- treated by standardize PPV, endolaser and silicone oil tamponade with or without DEX implant at the end of the surgery within 12 months from diagnosis of TRD;
- Hba1c is less than 10% with type 1 or 2 diabetes mellitus
Exclusion
- other concomitant ocular diseases that cause RD ( for example rhegmatogenous retinal detachment, exudative retinal detachment, other causes for TRD);
- any previous injection of DEX implant;
- abnormalities of the vitreoretinal interface, such as epiretinal membrane, vitreomacular traction without RD
Key Trial Info
Start Date :
June 15 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 15 2022
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05415826
Start Date
June 15 2022
End Date
September 15 2022
Last Update
June 13 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.